• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6744.TWO
Share

Feng Chi Biotech Corp. Stocks

NT$ 14.45Last Updated 14.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

NT$ 6.86M

NT$ 14.45
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Feng Chi Biotech Corp., a company based in Taipei, Taiwan, specializes in offering a diverse range of diagnostic and scientific services. Their core activities encompass genetic screening for both pre-implantation and prenatal stages, comprehensive life science support, and early detection screening for newborns. Additionally, they perform microbiological assessments for the food and pharmaceutical sectors, alongside engaging in medical translational research. The company also acts as a supplier for various genetic testing technologies and products specifically tailored for the field of oncology.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 19:00

SpaceX's strong results boosted U.S. stocks. Is the worst behind us?

21.10.2026 18:30

"The Music's Still Playing": What Wall Street Recommends Doing with Meta Shares Ahead of the Earnings Report

21.10.2026 16:57

"A Lifesaving Deal": Nvidia May Back Firmus After Its IPO Is Canceled

21.10.2026 16:27

"Value Is More Important Than Volume": Why Jefferies Expects Kazatomprom Shares to Rise 69%

21.10.2026 16:10

Shares of software developer Braze soared 50%. Salesforce is set to acquire it for the "wow factor."

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026